{{Rsnum
|rsid=10500991
|Gene=LUZP2
|Chromosome=11
|position=24828020
|Orientation=plus
|GMAF=0.08264
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=LUZP2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 74.3 | 22.1 | 3.5
| HCB | 88.3 | 11.7 | 0.0
| JPT | 86.7 | 11.5 | 1.8
| YRI | 100.0 | 0.0 | 0.0
| ASW | 98.2 | 1.8 | 0.0
| CHB | 88.3 | 11.7 | 0.0
| CHD | 87.2 | 12.8 | 0.0
| GIH | 80.2 | 18.8 | 1.0
| LWK | 99.1 | 0.9 | 0.0
| MEX | 69.0 | 31.0 | 0.0
| MKK | 94.2 | 5.8 | 0.0
| TSI | 84.3 | 15.7 | 0.0
| HapMapRevision=28
}}
{{PMID Auto GWAS
|PMID=19084217
|Trait=Serum markers of iron status
|Title=Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels
|RiskAllele=
|Pval=0.000002
|OR=NR
|ORtxt=NR
|OA=1
}}

{{PharmGKB
|RSID=rs10500991
|Name_s=
|Gene_s=LUZP2
|Feature=
|Evidence=PubMed ID:19084217; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. (Initial Sample Size: 459 twin pairs; Replication Sample Size: NR); (Region: 11p14.3; Reported Gene(s): LUZP2; Risk Allele: rs10500991-?); (p-value= 0.000002).This variant is associated with Serum markers of iron status.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740105
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10500991
|overall_frequency_n=8
|overall_frequency_d=128
|overall_frequency=0.0625
|n_genomes=8
|n_genomes_annotated=0
|n_haplomes=9
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}